These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 32586918)

  • 21. Comment on 'Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19' by Konig
    Sbidian E; Penso L; Herlemont P; Botton J; Baricault B; Semenzato L; Drouin J; Weill A; Dray-Spira R; Zureik M
    Ann Rheum Dis; 2023 May; 82(5):e117. PubMed ID: 32859610
    [No Abstract]   [Full Text] [Related]  

  • 22. The additive effects of hydroxychloroquine to maintenance therapy with standard of care in patients with systemic lupus erythematosus.
    Miyagawa I; Nakano K; Nakayamada S; Iwata S; Hanami K; Fukuyo S; Kubo S; Kawabe A; Miyazaki Y; Inoue Y; Ueno M; Ohkubo N; Fujita Y; Tanaka Y
    Int J Rheum Dis; 2020 Apr; 23(4):549-558. PubMed ID: 32020727
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The early protective effect of hydroxychloroquine on the risk of cumulative damage in patients with systemic lupus erythematosus.
    Akhavan PS; Su J; Lou W; Gladman DD; Urowitz MB; Fortin PR
    J Rheumatol; 2013 Jun; 40(6):831-41. PubMed ID: 23588942
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hydroxychloroquine-induced pigmentation in two patients with systemic lupus erythematosus.
    Reynaert S; Setterfield J; Black MM
    J Eur Acad Dermatol Venereol; 2006 Apr; 20(4):487-8. PubMed ID: 16643169
    [No Abstract]   [Full Text] [Related]  

  • 25. Clinical course of COVID-19 in patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine.
    Carbillon L; Benbara A; Boujenah J
    Ann Rheum Dis; 2021 Apr; 80(4):e54. PubMed ID: 32475831
    [No Abstract]   [Full Text] [Related]  

  • 26. Protective effect of hydroxychloroquine in systemic lupus erythematosus. Prospective long-term study of an Israeli cohort.
    Molad Y; Gorshtein A; Wysenbeek AJ; Guedj D; Majadla R; Weinberger A; Amit-Vazina M
    Lupus; 2002; 11(6):356-61. PubMed ID: 12139373
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Response to: 'Concerns and needs of patients with systemic lupus erythematosus regarding hydroxychloroquine supplies during the COVID-19 pandemic: results from a patient-centred survey' by Plüß
    Mathian A; Amoura Z
    Ann Rheum Dis; 2021 Apr; 80(4):e53. PubMed ID: 32616603
    [No Abstract]   [Full Text] [Related]  

  • 28. Hydroxychloroquine in systemic lupus erythematosus (SLE).
    Ponticelli C; Moroni G
    Expert Opin Drug Saf; 2017 Mar; 16(3):411-419. PubMed ID: 27927040
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Treatment of rheumatic diseases: current status and future prospective. Topics: II. Immunosuppressant/antirheumatic drugs; 10. Hydroxychloroquine].
    Yokogawa N
    Nihon Naika Gakkai Zasshi; 2011 Oct; 100(10):2960-5. PubMed ID: 22175138
    [No Abstract]   [Full Text] [Related]  

  • 30. Therapeutic efficacy and adverse events of hydroxychloroquine administration in Japanese systemic/cutaneous lupus erythematosus patients.
    Kishi C; Motegi SI; Yasuda M; Ishikawa O
    J Dermatol; 2018 Aug; 45(8):1020-1022. PubMed ID: 30133802
    [No Abstract]   [Full Text] [Related]  

  • 31. Initial hydroxychloroquine monotherapy in systemic lupus erythematosus: report of three cases.
    Ichikawa K; Kirino Y; Kunishita Y; Kishimoto D; Takase-Minegishi K; Yoshimi R; Nakajima H
    Mod Rheumatol Case Rep; 2021 Jul; 5(2):259-264. PubMed ID: 33533686
    [TBL] [Abstract][Full Text] [Related]  

  • 32. COVID-19 in systemic lupus erythematosus: Data from a survey on 417 patients.
    Ramirez GA; Gerosa M; Beretta L; Bellocchi C; Argolini LM; Moroni L; Della Torre E; Artusi C; Nicolosi S; Caporali R; Bozzolo EP; Dagna L;
    Semin Arthritis Rheum; 2020 Oct; 50(5):1150-1157. PubMed ID: 32927376
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Response to: 'Clinical course of COVID-19 in patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine' by Carbillon
    Konig MF; Gianfrancesco M; Yazdany J; Robinson PC
    Ann Rheum Dis; 2021 Apr; 80(4):e55. PubMed ID: 32475834
    [No Abstract]   [Full Text] [Related]  

  • 34. Hydroxychloroquine in systemic and autoimmune diseases: Where are we now?
    Dima A; Jurcut C; Arnaud L
    Joint Bone Spine; 2021 May; 88(3):105143. PubMed ID: 33515791
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical impact of hydroxychloroquine dose adjustment according to the American Academy of Ophthalmology guidelines in systemic lupus erythematosus.
    Vázquez-Otero I; Medina-Cintrón N; Arroyo-Ávila M; González-Sepúlveda L; Vilá LM
    Lupus Sci Med; 2020 May; 7(1):. PubMed ID: 32434863
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Response to hydroxychloroquine in Japanese patients with systemic lupus erythematosus using the cutaneous lupus erythematosus disease area and severity index (CLASI).
    Yokogawa N; Kato Y; Sugii S; Inada S
    Mod Rheumatol; 2012 Apr; 22(2):249-55. PubMed ID: 21842436
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hydroxychloroquine blood assay as a marker of nonadherence in patients with systemic lupus erythematosus: comment on the article by Koneru et al.
    Costedoat-Chalumeau N; Amoura Z; Marra D; Piette JC
    Arthritis Rheum; 2008 Jan; 59(1):153; author reply 153-4. PubMed ID: 18163410
    [No Abstract]   [Full Text] [Related]  

  • 38. Hydroxychloroquine and lupus pregnancy: review of a series of 36 cases.
    Buchanan NM; Toubi E; Khamashta MA; Lima F; Kerslake S; Hughes GR
    Ann Rheum Dis; 1996 Jul; 55(7):486-8. PubMed ID: 8774170
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dialogue: Hydroxychloroquine pharmacokinetic (PK) and exposure response in pregnancies with systemic lupus erythematosus: the importance of adherence for neonatal outcome.
    Bermas B; Costedoat-Chalumeau N
    Lupus Sci Med; 2022 Jan; 9(1):. PubMed ID: 34996859
    [No Abstract]   [Full Text] [Related]  

  • 40. Systematic analysis of COVID-19 infection and symptoms in a systemic lupus erythematosus population: correlation with disease characteristics, hydroxychloroquine use and immunosuppressive treatments.
    Gendebien Z; von Frenckell C; Ribbens C; André B; Thys M; Gangolf M; Seidel L; Malaise MG; Malaise O
    Ann Rheum Dis; 2021 Jun; 80(6):e94. PubMed ID: 32586921
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.